To describe the changes in the presentation of HIV-associated neurocognitive disorders (HAND) comparing the current combination antiretroviral therapy (cART) treatment era to the pre-cART era.
INTRODUCTION
In 2007, a revision to the existing diagnostic nomenclature and an algorithm was proposed by a working group sponsored by the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke to define HIV-associated neurocognitive disorders (HAND) [1] . The 2007 algorithm was an update from a previous nomenclature developed by the AIDS Task Force of American Academy of Neurology. The 2007 HAND algorithm defines three stages of increasing severity of cognitive impairment associated with HIV infection: HIV-associated asymptomatic neurocognitive impairment (ANI), HIV-associated mild neurocognitive disorder (MND), and HIV-associated dementia (HAD). An important modification from the 1991 criteria was the addition in the 2007 algorithm of the ANI category to describe HIV-seropositive (HIVþ) individuals with cognitive impairment defined by formal neuropsychological testing but without any impairment in the everyday functional tasks. HAND is defined by the clinical assessments of both neurocognitive performance and functional performance. Neuroimaging and laboratory tests are used to exclude confounding conditions. This review describes the changes in the clinical presentation of HAND with the introduction of combination antiretroviral therapy (cART) in 1996.
TEMPORAL PROGRESSION OF HIV-ASSOCIATED NEUROCOGNITIVE DISORDER
frequencies of milder stages of HAND, ANI and MND, have increased. In the pre-cART era, HAD was a progressive disorder leading to death within months. With cART, the majority of HIVþ individuals with HAND remains stable over many years.
A 
IMPACT OF AGING ON HIV-ASSOCIATED NEUROCOGNITIVE DISORDER
By 2015, it is anticipated that 50% of HIVþ individuals will be more than age 50 years [4] [5] [6] . More than 75% of HIV individuals over 50 now die from non-HIV-related causes [5] , suggesting that the causes of cognitive impairment among older HIVþ individuals may overlap with those among elderly HIV-individuals such as cerebrovascular disease or neurodegenerative diseases. The aging of the HIVþ population may lead to changes in the neuropsychological test profile of HAND. Indeed, one study comparing the neuropsychological testing of HIVþ individuals more than age 50 years to HIVþ individuals less than age 50 years suggests a higher proportion of amnestic cognitive impairment among the older individuals compared with the younger individuals with HIV infection [7 & ]. The prevalence of motor signs of Parkinsonism such as bradykinesia and tremor is currently less in HIVþ individuals on cART compared with the pre-cART era; although with an aging HIVþ population, this reduction in motor symptoms may lessen.
FREQUENCY OF NEUROCOGNITIVE IMPAIRMENT AND IMPACT OF COMORBIDITIES
As noted above and recognized by the researchers and clinicians alike, there is a reduction in the severity of neurological and neurocognitive deficits associated with HIV after the introduction of cART. Dramatic downward shifts in the incidence of HAD were evident, although increased longevity led to an overall increased prevalence of this more severe form of HAND [8] . Recently published results on the cohorts continue to find increased neurocognitive impairment prevalence rates in those on cART and suppressed systemic viral load as previously found in 2007 [9,10 & ]. In the CHARTER (CNS HIV Antiretroviral Therapy Effects Research) baseline study [11] , approximately 30% continue to have neurocognitive impairment in those who were suppressed with CD4 þ counts greater than 200 and without substantial comorbidities. In HIVþ individuals with contributing comorbidities, irrespective of the CD4 lymphocyte count and viral load suppression, approximately 60% have neurocognitive impairment, and in HIVþ individuals with confounding comorbidities, irrespective of the CD4 lymphocyte count and viral load suppression, approximately 80% have neurocognitive impairment.
CHANGES IN THE NEUROPSYCHOLOGICAL TEST PROFILE OF HIV-ASSOCIATED NEUROCOGNITIVE DISORDER
Prior studies have demonstrated a change in the pattern of neurocognitive impairments along with the shift in the severity of deficits. An early study in this area combining two cohorts, monotherapy versus combination therapy, documented a shift to deficits in the learning domain from pre-cART to post-cART eras [12] . A later study from the CHARTER and HNRC (HIV Neurobehavioral Research Center) groups [13] found that in medically asymptomatic HIVþ individuals, cognitive impairment was more common in a cART (2000-2007, n ¼ 937) sample compared with a pre-cART (1988-1995, n ¼ 857) sample. There was a shift from the prior slowed motor and speed of processing deficits in the precART era to an impact on learning, memory, and executive functioning in the cART era. Recent studies have also confirmed a shift in the pattern
KEY POINTS
The frequency of the most severe stage of HIVassociated neurocognitive disorder (HAND), HIVassociated dementia (HAD), has decreased, but the frequencies of milder stages of HAND, asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder (MND), have increased.
With combination antiretroviral therapy, the majority of HIVþ individuals with HAND remains stable over many years.
The aging of the HIVþ population may lead to changes in the neuropsychological test profile of HAND.
SIGNIFICANCE OF THE ASYMPTOMATIC NEUROCOGNITIVE IMPAIRMENT STAGE OF HIV-ASSOCIATED NEUROCOGNITIVE DISORDER
With the shift from the more severe impairments of HAD to the predominance of milder forms of HAND, there has also been a shift in the clinical and research focus on ameliorating these milder forms and protecting the CNS for what is now a chronic disease in many living with HIV. ANI continues to be a compelling diagnostic category in HAND. Some researchers believe that the prevalence of HIV-related cognitive impairment is currently being overestimated through the use of neurocognitive assessment [14] . However, biomarker studies demonstrate that there is neuronal injury in those who are neuroasymptomatic with HIV infection [3 & ]. Multiple studies have also demonstrated that neurological injury can occur early in HIV disease [15 & ]. A milestone publication from the CHARTER group recently demonstrated that those with ANI are 2-5 times more likely to progress to symptomatic neurocognitive impairment [16 && ]. This demonstrates the need for effective early identification and treatment of those who are not already on ART, and the potential need to screen for any other treatable causes of neurocognitive impairment.
IMPACT OF CENTRAL NERVOUS SYSTEM PENETRATION OF COMBINATION ANTIRETROVIRAL THERAPY FOR THE TREATMENT OF HIV-ASSOCIATED NEUROCOGNITIVE DISORDER
Treatment of HAND is predominantly with cART. Some antiretroviral drugs may have better penetration into the CNS than other antiretroviral drugs, but it is unclear whether a combination of antiretroviral drugs with better penetration into the CNS has a beneficial impact on neurocognitive performance. One study suggests that cART with better CNS penetration is associated with improved CSF HIV viral suppression compared with cART with less CNS penetration [17] . However, a recent randomized trial of HIVþ individuals with HAND treated with a CNS-targeted cART with good CNS penetration compared to a non-CNS-targeted cART with poor penetration showed no benefit in the neurocognitive performance for the CNS-targeted cART arm [18 & ]. In addition, a recent large study of 61 938
HIVþ individuals followed for 37 months found that initiation of cART with better CNS penetration increased the risk of HIV dementia, suggesting a potential deleterious effect from cART with better CNS penetration [19 & ].
HIV-ASSOCIATED NEUROCOGNITIVE DISORDER IN THE INTERNATIONAL SETTINGS
As studies in resource-limited countries expand, HAND is increasingly being recognized as a neurological complication of HIV infection in the international settings. Almost 70% of the world's HIV population resides in the sub-Saharan Africa, where people are infected not with HIV subtype B which is predominant in North America but rather with HIV subtypes C, A, and D. Initial studies in which HIV subtypes A and D are predominant suggest that the overall frequency of HAD is high (31%) in untreated HIVþ individuals [20] , but this frequency of dementia resembles the overall frequency of HAD in precART cohorts in North America. If this frequency of HAD is seen throughout sub-Saharan Africa and other resource-limited countries, then HAD may be along with Alzheimer's disease and vascular dementia among the top three causes of dementia globally. However, unlike Alzheimer's disease and vascular dementia, HAD is potentially reversible if it can be identified early, and cART can be initiated. The pattern of deficits in Uganda includes psychomotor slowing, executive dysfunction and verbal memory deficits, and is similar to the profile seen in the United States studies [21] . The neuropsychological profile from the regions in Africa where HIV subtype C is predominant, for example, South Africa, shows similar results [22] . Additional studies are needed to determine whether specific HIV subtypes are associated with either an increased or decreased frequency of HAND.
CONCLUSION
In conclusion, HAND continues to be an important neurological manifestation in both HIVþ individuals naïve to cART and on cART. Future studies will determine to what degree age-related comorbid conditions, such as vascular disease or neurodegenerative conditions including Alzheimer's disease, will contribute to the cognitive impairment in HIVþ individuals on cART who survive longer and advance in age.
